CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review

Mingyu Ye, Lei Gao, Tao Wang, Jiechen Yu, Jiaping Gui, Jianmin YangFrontiers in Oncology 2022 · DOI

This case report, published in Frontiers in Oncology, details a potential breakthrough in treating one of the most aggressive blood cancers: Burkitt lymphoma (BL). Researchers from the Naval Medical University in Shanghai demonstrate that combining autologous stem cell transplantation (ASCT) with CD19-targeted CAR-T cell therapy can lead to long-term, durable remission in high-risk, older patients.

TL;DR

Researchers report the first successful use of ASCT followed by CD19 CAR-T therapy as a consolidation strategy for a 61-year-old patient with high-risk Burkitt lymphoma. The patient achieved complete remission that has persisted for over four years, suggesting this "one-two punch" approach is both safe and highly effective for a demographic that typically faces poor outcomes.

What Problem Does This Paper Address?

Burkitt lymphoma (BL) is a "hyper-aggressive" non-Hodgkin lymphoma. While younger patients often respond well to intensive chemotherapy, the outlook for patients over 60 is grim, with 3-year progression-free survival (PFS) rates hovering around 56%. When the disease relapses or becomes refractory (resistant to treatment), salvage options are limited.

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of other B-cell malignancies, but its efficacy in BL—especially in older, high-risk patients—remains under-explored. The challenge is twofold: BL grows incredibly fast, often outpacing the manufacturing time for CAR-T cells, and the immunosuppressive tumor environment can hinder CAR-T persistence.

Methods

The authors describe a clinical course for a 61-year-old male with high-risk BL (characterized by high LDH levels and 79% bone marrow involvement). The treatment strategy followed a specific sequence:

  1. Induction & Alternative Therapy: Standard chemotherapy (VDCP) followed by intensive regimens (Hyper-CVAD-A, MAVP) to reduce tumor burden.
  2. ASCT (The Bridge): The patient underwent autologous stem cell transplantation using a CEAC conditioning regimen (semustine, etoposide, cytarabine, and cyclophosphamide).
  3. CAR-T Infusion (The Consolidation): Seven days after the stem cell transplant, the patient received an infusion of CD19-targeted CAR-T cells (6 × 10⁶ cells/kg).
  4. Monitoring: The team tracked cytokine levels (to monitor for Cytokine Release Syndrome) and used qPCR to measure the in vivo expansion and persistence of the CAR-T cells over 48 months.

Datasets

As a Case Report, the primary "dataset" is the longitudinal clinical data of a single patient. However, the authors supplement this with a Literature Review (Table 1), aggregating data from five previous trials/reports involving 41 total patients treated with CAR-T for Burkitt lymphoma. This allows them to compare their "ASCT + CAR-T" approach against other strategies.

Key Insights and Ideas

  • The Synergy of ASCT and CAR-T: The authors hypothesize that ASCT does more than just kill cancer cells; it "clears the field." By deeply depleting regulatory T cells (which normally inhibit CAR-T function) and reducing the overall tumor burden, ASCT creates an ideal physiological environment for the CAR-T cells to expand and persist.
  • Phenotype Matters: The CAR-T product used in this case was rich in "naive" (32.8%) and "central memory" (44.7%) T cells. These subsets are known to be more durable and effective than "effector" T cells, which tend to burn out quickly.
  • The 4-1BB Advantage: The CAR construct utilized a 4-1BB costimulatory domain. Compared to the more common CD28 domain, 4-1BB is associated with slower, more sustained T-cell expansion and lower metabolic exhaustion.
  • Bimodal Expansion: Interestingly, the CAR-T cells showed two distinct peaks in the blood: one at 6 days post-infusion and a surprising second peak at 38 months. This second peak coincided with a slight enlargement of lymph nodes, suggesting the CAR-T cells "re-awakened" to eliminate a potential micro-relapse.

Key Results

  • Durable Remission: The patient achieved Complete Remission (CR) and has remained cancer-free for 48 months (4 years) at the time of publication.
  • Safety Profile: Despite the patient's age and the intensive nature of the treatment, he only experienced Grade 1 Cytokine Release Syndrome (mild fever) and no neurotoxicity.
  • Long-term Persistence: CAR-T cells remained detectable in the peripheral blood for the entire 48-month follow-up period, reaching a concentration of 7.78 × 10⁴ copies/ug gDNA at the four-year mark.

Limitations and Future Work

The most obvious limitation is the sample size (N=1). While the results are compelling, a single case report cannot establish a new standard of care. Furthermore, the specific "recipe" of chemotherapy used before ASCT was quite intensive, which may not be tolerable for all elderly patients.

The authors conclude that larger, multi-center clinical trials are necessary to validate this combination therapy. Future research will also need to focus on the "re-activation" mechanism of CAR-T cells to understand how they manage to provide such long-term surveillance against aggressive relapses.

Summary updated

Abstract

Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antigen receptor T cells (CART) have achieved remarkable success in the treatment of B-cell leukemia and lymphoma. Here, for the first time, we report a 61-year-old, high-risk BL patient with autologous stem cell transplantation (ASCT) bridging therapy prior to CART as consolidation therapy. Our findings demonstrate that the combination of ASCT and CART for BL is safe and feasible.
BibTeX
@inproceedings{ye2022cd,
  author = {Mingyu Ye and Lei Gao and Tao Wang and Jiechen Yu and Jiaping Gui and Jianmin Yang},
  title = {{CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.932254},
}
Figure